Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Joseph Schwartz

Why Maze Therapeutics, Up 55%, Was Shocked By Its Own Test Results

Maze Therapeutics catapulted Thursday after its experimental treatment for a rare, genetic disease blew past the company's own expectations.

Investors Business Daily

Sarepta Sells Arrowhead Stake To Stretch Its Cash Runway; And One Stock Dives

Arrowhead Pharmaceuticals stock tumbled Thursday after Sarepta Therapeutics liquefied its entire stake in the smaller biotech company.

Investors Business Daily

Insmed Is Trading At A 25-Year High. Will Its 'Skeleton Key' Work?

Insmed stock is soaring as it approaches the potential approval of its second drug. CEO Will Lewis calls it a "skeleton key."

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Sarepta's 'Unprecedented Times' Continue As Company Rebukes The FDA

Sarepta stock took another dive Monday after the biotech company refused the FDA's request to voluntarily stop all shipments of Elevidys.

Investors Business Daily

Ultragenyx Pharma Takes Another Hit As FDA Slaps Its Gene Therapy With A Rejection

Ultragenyx Pharmaceuticals took another hit when the FDA rejected its gene therapy for patients with a rare, genetic disorder.

Investors Business Daily

How KalVista Pharma Is Taking On A Rare But Deadly Disease

Biotech stock KalVista has soared recently, as the firm looks to fundamentally change the treatment landscape for HAE patients.

Investors Business Daily

IBD Stock Of The Day Travere Therapeutics: A Breakout And $1 Billion Opportunity Loom

Travere Therapeutics is Friday's IBD Stock Of The Day. The biotech stock is eyeing two potential entries and a second approval for Filspari.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Wave Life Sciences Just Edited RNA. Why Its Key Rival, Korro Bio, Skyrocketed.

Shares of Wave Life Sciences surged Wednesday after the company announced "impressive" proof-of-concept results for its new technology.

Investors Business Daily

Ascendis Rockets — And Hammers BioMarin — On New Results For Growth Drug

Ascendis Pharma stock rocketed Monday on promising test results for a growth treatment that could rival BioMarin's approved drug, Voxzogo.

Investors Business Daily

Travere Stock Pops After Snagging Full Approval For Calliditas Rival In Kidney Disease

Travere Therapeutics stock surged Friday after the biotech company snagged full FDA approval for its kidney disease treatment, Filspari.

Investors Business Daily

Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test

Sarepta stock jumped Thursday after Pfizer's rival gene therapy for Duchenne muscular dystrophy failed in final-phase testing.

Investors Business Daily

Crinetics Unveils 'Stunning' Results In Highly Anticipated Study

Crinetics unveiled "stunning" results from a study of a major drug. Crinetics stock rose Monday.

Investors Business Daily

Why Former Highflier Travere Therapeutics Just Crashed 41% To A Decade-Low

Travere said Thursday its kidney disease drug failed to pass muster in a confirmatory study, and TVTX stock crashed to a 10-year low.

Investors Business Daily

Aurinia Surges As It Explores 'Strategic Alternatives,' Including A Potential Buyout

Aurinia Pharmaceuticals said it's exploring strategic alternatives, including a potential buyout, leading AUPH stock to surge Friday.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Sarepta Stock Catapults Higher After Eking Out A Narrow Win In Its Gene Therapy Battle

Shares of SRPT stock launched Monday after FDA advisors voted late Friday in support of a highly anticipated gene therapy from Sarepta.

Investors Business Daily

Sarepta Tumbles As Report Of Internal FDA Strife Scorches Its Gene Therapy

Several FDA staffers were leaning toward rejecting a highly watched gene therapy from Sareptas, according to a report Thursday.

Investors Business Daily

The FDA Just Approved Its Most Expensive Drug Ever — Sending UniQure Stock On A Warpath

The FDA just approved its most expensive drug ever — a hemophilia gene therapy from CSL and UniQure — and QURE stock popped Wednesday.

Investors Business Daily

Why IBD Stock Of The Day Sarepta Just Snagged A Price Target Hike Over Pfizer

IBD Stock Of The Day Sarepta will lead the gene therapy market in treating a form of muscular dystrophy, an analyst said Monday.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Highly Rated Avidity Biosciences Hammered After Side Effect Sidelines Study

The FDA placed a myotonic dystrophy study from Avidity Biosciences on partial hold Tuesday, leading RNA stock to collapse.

Investors Business Daily

Why Pharvaris Stock Crashed — And Why At Least One Analyst Isn't Worried

Biotech stock Pharvaris plummeted Monday after the Food and Drug Administration placed a pair of its clinical studies on hold.

Reuters

'Not many of us left': France races to record memories of 1942 Jewish roundup

When police came knocking on the door of his eastern Paris home on July 16, 1942, 15-year-old French Jew Joseph Schwartz was no longer there. Forewarned, he and his father Lejbus had gone into hiding.

Investors Business Daily

Travere Therapeutics Pops After Snagging Priority Review For A New Kidney Drug

The FDA accepted Travere Therapeutics' application for a kidney disease treatment on Monday, leading TVTX stock to surge higher.

Investors Business Daily

Ascendis Reverses Its Losses After A Key Drug Misses Sales Forecasts

Biotech stock Ascendis Pharma reversed early losses Thursday to close with a gain despite a first-quarter miss for Skytrofa.

Investors Business Daily

Reata Stock Enjoys A Two-Day Climb — Why It Could Still Be Facing Everest

U.S. officials will soon examine Reata's request to treat a neurodegenerative condition, and RETA stock continued its two-day climb Friday.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.